Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country symbols : Sls save search
SELLAS Life Sciences Announces Proposed Public Offering - Jan 04, 2024
Published: 2024-01-04 (Crawled : 08:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -31.99%
H: 1.66%
C: -5.55%
life offering sciences
SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-09 (Crawled : 00:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: 0.87%
H: 0.0%
C: -4.21%
business update financial results
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia
Published: 2023-04-20 (Crawled : 14:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: 0.0%
H: 4.49%
C: -5.77%
gfh009 life sciences leukemia trial
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -1.26%
H: 8.94%
C: 5.53%
life trial
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
Published: 2022-12-06 (Crawled : 18:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -0.4%
H: 1.59%
C: -3.19%
gfh009 preclinical life program cancer
SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit
Published: 2022-11-30 (Crawled : 14:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -3.0%
H: 5.75%
C: 5.75%
sciences life
SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
Published: 2022-11-02 (Crawled : 13:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -1.46%
H: 2.11%
C: -15.82%
sciences life update study
SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S
Published: 2022-10-11 (Crawled : 13:20) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -1.08%
H: 5.98%
C: -2.17%
life trial china phase 1
SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting
Published: 2022-09-22 (Crawled : 13:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: 4.07%
H: 4.13%
C: 0.43%
sciences meeting life presentation
SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th
Published: 2022-09-14 (Crawled : 13:20) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -0.32%
H: 1.62%
C: -2.92%
sciences conference life
SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022
Published: 2022-09-08 (Crawled : 18:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -1.67%
H: 5.76%
C: 3.39%
sciences life symposium
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
Published: 2022-08-24 (Crawled : 13:20) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -0.6%
H: 3.03%
C: 2.42%
gfh009 preclinical life cancer growth prostate cancer in vitro
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
Published: 2022-05-26 (Crawled : 13:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: 6.49%
H: 0.0%
C: -11.59%
keytruda trial cancer phase 1 ovarian cancer
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer
Published: 2022-02-01 (Crawled : 14:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: 9.2%
H: 4.31%
C: 3.93%
ovarian cancer trial phase 1 cancer life science enroll
SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th
Published: 2021-09-14 (Crawled : 13:15) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -0.83%
H: 4.08%
C: 1.25%
life science conference
SELLAS Life Sciences Announces USPTO Decision to Grant New Patent for Galinpepimut-S in Combination with Checkpoint Inhibitor Therapies- Patent term extends to at least 2036 -
Published: 2021-05-27 (Crawled : 16:00) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: 1.56%
H: 7.5%
C: 3.08%
life science patent therapy
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.